The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By

Whinstone Inc. – Subsidiary of Northern Data AG

Advising Northern Data AG, a Germany based developer and operator of high-performance computing (“HPC”) infrastructure solutions, on the sale of its U.S. subsidiary Whinstone Inc., an HPC data center operator based in Rockdale, Texas, to Riot Blockchain Inc., a U.S. based publicly-traded bitcoin miner

Acacia Pharma Group plc

Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share

Kenedix

Advising Kenedix, one of the largest Japanese independent real estate asset managers, on its acquisition by Sumitomo Mitsui Finance and Leasing, one of the largest Japanese leasing companies

Learning Materials for the K-12 Segment in Spain

Advising Sanoma Oyj (HEL: SAA1V), a European learning and media company listed on Nasdaq Helsinki, on the acquisition of Santillana Spain, a leading Spanish provider of K-12 learning materials, from Promotora de Informaciones S.A. (Grupo Prisa, BME: PRS)

Axión Group

Advised AMP Capital on the sale of its portfolio company Axión Group, a leading independent broadcasting and telecommunications infrastructure provider in Spain, to Asterion Industrial Partners, a Spanish infrastructure fund

Cosmetic applications endolysin

Advised Micreos, a fast-growing biotechnology company, on a long-term license agreement with L’Oréal for one of Micreos’ phage-based active ingredients, SA.100

VX Fiber

Advised VX Fiber, an international infrastructure and technology business focused on Fibre-to-the-Home networks, on its sale to the infrastructure fund AMP Capital

Community Fibre Limited

Advised Warburg Pincus LLC and Deutsche Telekom Capital Partners on the acquisition of a majority stake in CommunityFibre Limited, a leading full fibre network infrastructure platform in UK

Equity stake in Bupa Arabia

Advising Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, the largest health insurance provider in the Kingdom of Saudi Arabia

Centrifuge and processing equipment business of Koki Holdings Co., Ltd.

Advised Eppendorf AG, a leading family-owned life science company, on the acquisition of the centrifuge and processing equipment business of KKR-owned Koki Holdings Co., Ltd., a manufacturer of power tools and centrifuge and processing equipment

Global rights (excluding North America) to ThermaCare (United Kingdom)

Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the global rights (excluding North America) for ThermaCare, including a dedicated manufacturing facility based in Albany, Georgia, USA, to Angelini Pharma

Asia and US rights to Physiogel

Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the rights to Physiogel Asia and the US to Korea-based LG Household & Health Care Ltd

50:50 Joint Venture (Australian Unity)

Advised Australian Unity, an Australian healthcare, financial services and retirement and living services company, on the formation of a strategic 50:50 joint venture with Keppel for investment opportunities in the Australian metropolitan office property sector

Wildstone

Advised Wildstone, a leading aggregation and digitalization company for outdoor billboards, on its sale to Digital Colony, whilst contemporaneously acquiring Insite Poster Group

FTTH network including 933,000 BU’s

Advising MasMovil, the fourth largest Spanish telecom operator, in the sale of part of its fibre-to-the-home (FTTH) network to an international infrastructure fund. The transaction perimeter includes 933,000 homes across 5 main Spanish cities

Assets owned by GlaxoSmithKline plc

Advised GlaxoSmithKline plc, the UK listed international pharmaceutical and consumer healthcare company, on the divestment of Horlicks and other consumer healthcare nutrition brands to Unilever plc, and on the merger of GSK Consumer Healthcare Limited with Hindustan Unilever Limited

IslaLink

Advised EQT, a leading alternative investments firm with more than EUR 37 billion of AUM on the sale of its portfolio company IslaLink, a leading neutral and independent submarine fiber infrastructure operator in the Balearic Islands

Novartis AG’s 36.5% stake in Consumer Health Joint Venture

Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture

Grupo Sidecu

Advised the shareholders of Grupo Sidecu, the leading concessional sport center operator in Spain, on its sale of a controlling stake to Portobello Capital, a local private equity fund

MorphoSys AG

Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab

Hirslanden Private Hospital Group

Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt

Portfolio of 119 marketed and development pipeline products from Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 119 marketed and development pipeline products to Rivopharm SA

Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).

Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)

Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).